Bain Capital Public Equity Management’s Puma Biotechnology PBYI Stock Holding History

Bain Capital Public Equity Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-657,876	Closed	-$73.6M	–	100
2017 Q3	$78.8M	Buy	657,876 +318,882	+94%	+$29.7M	4.97%	3
2017 Q2	$29.6M	Buy	338,994 +252,294	+291%	+$14.1M	1.78%	20
2017 Q1	$3.23M	Buy	+86,700	New	+$3.16M	0.23%	52
2014 Q1	–	Sell	-401,330	Closed	-$41.5M	–	54
2013 Q4	$41.5M	Buy	401,330 +68,539	+21%	+$4.02M	1.17%	33
2013 Q3	$17.9M	Sell	332,791 -411,612	-55%	-$22.2M	0.45%	39
2013 Q2	$33M	Buy	+744,403	New	+$26.2M	0.77%	37

Other funds holding PBYI

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bain Capital Public Equity Management's PBYI Position: Q4 2017 in Review

Bain Capital Public Equity Management sold out of Puma Biotechnology (PBYI) in Q4 2017, closing a stake of 657,876 shares — an estimated $73.6M sold.

Bain Capital Public Equity Management first reported a position in PBYI in Q2 2013 and held it in 6 quarters. The position peaked at $78.8M in Q3 2017. 203 funds tracked by Wall St. Rank hold PBYI as of Q4 2017.

Bain Capital Public Equity Management reported no remaining Puma Biotechnology position as of Q4 2017 after selling out during the quarter.
Bain Capital Public Equity Management sold 657,876 Puma Biotechnology shares in Q4 2017, an estimated $73.6M.
Bain Capital Public Equity Management first reported a position in Puma Biotechnology in Q2 2013 and held it in 6 quarters.
Bain Capital Public Equity Management's Puma Biotechnology position peaked at $78.8M in Q3 2017.
203 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2017.

Based on Bain Capital Public Equity Management's 13F filing for Q4 2017, filed 14 Feb 2018.